Artiva Biotherapeutics grants director 13,750 options

Artiva Biotherapeutics disclosed a new 13,750-share stock option grant to a director with a $10.88 exercise price and vesting tied to the 2027 meeting.

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. (ARTV) reported that director Laura Stoppel received a grant of 13,750 stock options on September 8, 2026. These options have an exercise price of $10.88 per share and become fully vested on the earlier of September 8, 2027, or the company’s 2027 annual stockholder meeting. The options expire on September 7, 2036, and no Rule 10b5-1 trading plan is reported for this grant.

Insider Trade Summary

Grant/Award: 13,750 shares

Grant/Award 1 txn

Insider Stoppel Laura

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy) F1	13,750	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 13,750 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

Key Figures

Options granted: 13,750 options Exercise price: $10.88 per share Underlying shares: 13,750 shares +2 more

5 metrics

Options granted 13,750 options Director stock option grant on September 8, 2026

Exercise price $10.88 per share Exercise price of director stock options granted September 8, 2026

Underlying shares 13,750 shares Artiva Biotherapeutics common stock underlying the option grant

Vesting date trigger September 8, 2027 Options vest in full on the earlier of this date or the 2027 annual meeting

Expiration date September 7, 2036 Expiration of director stock options granted on September 8, 2026

Key Terms

Director Stock Option, vest in full, annual stockholder meeting

3 terms

Director Stock Option financial

"The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting."

vest in full financial

"The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting."

annual stockholder meeting financial

"The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting."

An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ARTV disclose in this Form 4?

ARTV disclosed that director Laura Stoppel received a grant of 13,750 stock options on September 8, 2026. The options relate to Artiva Biotherapeutics common stock and were awarded as a compensation-related acquisition rather than an open-market purchase.

What is the exercise price of the new Artiva Biotherapeutics (ARTV) stock options?

The newly granted options to the ARTV director carry an exercise price of $10.88 per share. This is the price at which the holder may buy Artiva Biotherapeutics common stock upon exercising the options, once they are vested.

When do the newly granted ARTV director stock options vest?

The 13,750 options granted to the ARTV director will vest in full on the earlier of September 8, 2027, or the date of Artiva Biotherapeutics’ 2027 annual stockholder meeting, according to the footnote describing the vesting schedule.

What is the expiration date of the director stock options reported by ARTV?

The director stock options reported by ARTV expire on September 7, 2036. After this expiration date, any unexercised options will no longer be exercisable for Artiva Biotherapeutics common stock.

Does the ARTV Form 4 indicate a Rule 10b5-1 trading plan for this grant?

No. The Form 4 indicates that no Rule 10b5-1 trading plan is reported in connection with this option grant to the ARTV director, meaning the award was not disclosed as being made under a pre-arranged trading plan.

How many ARTV shares are underlying the new director stock option grant?

The option grant to the ARTV director covers 13,750 shares of Artiva Biotherapeutics common stock as the underlying security. This matches the number of option rights awarded in the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 05:58 PM EDT Accepted by SEC EDGAR 09/08/2026 - 05:58 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stoppel Laura

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$10.88	09/08/2026		A		13,750		(1)	09/07/2036	Common Stock	13,750	$0	13,750	D

Explanation of Responses:

1. The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

	/s/ Jennifer Bush, Attorney-in-Fact	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)